Two anti-IL-31 mAbs. Two full portfolios. A $1.3B+ market in motion.
Enter your email for free access.
The full competitive brief every animal health marketing leader, commercial director, brand team, and veterinary affairs professional needs to navigate the canine derm competitive landscape. Two anti-IL-31 mAbs. Two full portfolios. A $1.3B+ market in motion.
Both Cytopoint (lokivetmab) and Befrena (tirnovetmab) are anti-IL-31 monoclonal antibodies, they block the same itch-signaling cytokine that drives atopic dermatitis in dogs. IL-31 binds receptors on sensory neurons and skin cells to trigger chronic itch, inflammation, and skin barrier disruption. Neutralizing it upstream reduces itch intensity at the source rather than suppressing the immune system broadly.
That shared mechanism is strategically significant: when clinics ask "what's the difference?" the honest molecular answer is nuanced. Both products neutralize IL-31. The commercial differentiation lives in safety track record, dosing flexibility, real-world outcomes data, and the portfolio context each brand lives inside.
Because mechanism is shared, the clinical narrative cannot be built on mechanism alone. Winning clinics on "we also block IL-31" is a race to the bottom. The durable position belongs to the brand with the deepest safety data, the most flexible dosing story, and the most embedded clinic workflows.
Befrena's 6-week minimum will be positioned as an "extended protection" advantage. The clinically honest counter is that Cytopoint's 4-week option isn't a limitation, it's flexibility calibrated to the patient. Severely atopic dogs often need shorter intervals; the ability to titrate frequency to severity is a clinical strength, not a compliance weakness.
The injectable mAb competition is one piece of a larger portfolio story. Both Elanco and Zoetis now approach clinic derm conversations with multi-product depth, spanning oral therapies, injectable biologics, and in Zoetis's case, integrated diagnostics.
Both Elanco and Zoetis now bring multi-product derm portfolios to clinic conversations. Elanco leads with three treatment mechanisms; Zoetis pairs two treatments with diagnostics and a deeper clinical data record. The organization that helps clinics build a more efficient, outcomes-focused derm workflow will build the most durable position in this category.
Category decisions in veterinary derm are not made by brand preference alone. They are made through a complex interaction of protocol inertia, staff training, client familiarity, inventory economics, and rep relationships.
Clinics with established Cytopoint reorder routines, reminder protocols, and staff workflows carry meaningful switching friction. The cost of changing isn't just price, it's retraining, reordering, updating EMR reminders, and re-educating clients.
Pet owners with atopic dogs who've seen results on Cytopoint are the hardest switch. "It works" is the most powerful retention statement.
Clinics optimize for fast inventory turns and predictable reorder cycles. Adding a new mAb means managing two SKUs for the same indication, a complexity tax that works against switching.
The highest-risk segment: newly diagnosed atopic patients with no product loyalty. Befrena will win disproportionately on first-prescription opportunities in clinics where the Elanco rep relationship is strong.
The next 90 days are the most consequential inflection point in canine derm since Apoquel launched in 2013. Five signals will define how this market shapes for the next three years.
Organized by role. The derm competitive response is not a single team's problem, it spans brand, commercial, field, and veterinary affairs. Here is where each function needs to focus.
The organizations still building that answer when Befrena achieves full national availability are already behind. The window to shape clinic and market perception is open right now, and it will not stay open indefinitely.
Weekly competitive intelligence for animal health marketing and commercial leaders. Launches, earnings, field signals, and strategic analysis, delivered before it's common knowledge.